| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Zentalis Pharmaceuticals, Inc. | SVP, Clinical Development | Stock Option (Right to Buy) | 24.2K | $1.16M | $47.80 | 10 Feb 2022 | Direct |
| Zentalis Pharmaceuticals, Inc. | SVP, Clinical Development | Common Stock | 16K | $164K | $10.29 | 14 Feb 2022 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| ZNTL | Zentalis Pharmaceuticals, Inc. | 10 Feb 2022 | 4 | -$30.2K | 4 | SVP, Clinical Development | 14 Feb 2022, 20:10 |
| ZNTL | Zentalis Pharmaceuticals, Inc. | 18 Jan 2022 | 15 | -$1.3M | 4 | SVP, Clinical Development | 20 Jan 2022, 18:15 |